Market Cap 7.92M
Revenue (ttm) 0.00
Net Income (ttm) -5.45M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 104,500
Avg Vol 147,390
Day's Range N/A - N/A
Shares Out 21.41M
Stochastic %K 35%
Beta 1.50
Analysts Strong Sell
Price Target $8.00

Company Profile

Kairos Pharma, Ltd., a clinical-stage biopharmaceutical company, develops immunotherapy and cell therapies for the treatment of cancer. The company offers therapeutics, including antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer, and glioblastoma. It also develops ENV 105, an antibody therapeutic that is in a Phase 2 clinical trial for prostate cancer patients resistant to androgen-targeted therapy, as well as in a Phase 1 clinical trial for non-smal...

Industry: Biotechnology
Sector: Healthcare
Phone: 310 948 2356
Address:
2355 Westwood Blvd., Suite 139, Los Angeles, United States
Oldshoe
Oldshoe Jul. 4 at 4:55 PM
$KAPA Bullish based on current stock price and current market opinion of KAPA (both low). NFA
0 · Reply
Oldshoe
Oldshoe Jul. 4 at 4:53 PM
$KAPA I estimate split by ~7/15, announcement two days prior. IB6 restrictions apply (expect IB6 restrictions continue to apply into Q4) - so price decline means it's to company's advantage to do any cash raise soon - but the compliance situation means it's unlikely pre-split. Inflow needed for cash raise, so catalyst needed. First catalyst (smaller one, there are potentially several) likely to occur as early as a few days after split, or later in Q3. Subsequent catalysts in Q3/Q4 - when everything is in place and company timing - company currently has over two quarters' cash on hand. Very much aware of January S-3 dollar amount - but their actual current ATM ability is only ~$2 million. Even that much could be absorbed by the market fairly easily during a high volume favorable catalyst situation (but would expect some moderation on ATM sells). Some variation of that scenario. Straight up opinion only, not financial advice, do your own due diligence before investing in a stock.
0 · Reply
Xtracked
Xtracked Jul. 3 at 3:35 PM
$KAPA MNTS got approved for NASA contract yesterday. Benzinga views NASA files. I expect a formal PR next week. ;) NFA
0 · Reply
Xtracked
Xtracked Jul. 3 at 3:31 PM
$KAPA I got out last week, already made $ w funds. This was the farthest I've gone w a carrot dangling in front on me. Never again. I'll be back as well to take advantage of this POS as much as possible.
0 · Reply
ezcheezie
ezcheezie Jul. 2 at 5:52 PM
$KAPA My positition is finally closed out. GLTA, I'll keep this on my watch list, but I'm not touching it until after the R/S.
0 · Reply
Xtracked
Xtracked Jul. 2 at 9:46 AM
0 · Reply
Xtracked
Xtracked Jul. 2 at 9:42 AM
$KAPA Whos buying this trash? They will end up diluting before they lie about any results . "Collaborations will continue thru 2027".. that'll be the PR they will present
0 · Reply
stockforce123
stockforce123 Jul. 1 at 8:42 PM
$KAPA “key collaborations with pharmaceutical companies that test the synergy of ENV-105 with oncology drugs for prostate cancer by end of Q2/beginning of Q3 2026”. JNJ
0 · Reply
stockforce123
stockforce123 Jul. 1 at 4:19 PM
$KAPA Jumped back in today with $10K. The CEO said collaboration with BP will be announced by early Q3. It could be JNJ.
0 · Reply
Oldshoe
Oldshoe Jul. 1 at 12:07 AM
$KAPA Outcome of vote removes some uncertainty. Delisting risk effectively removed since they can r/s. Company has adequate mkt cap.
0 · Reply
Latest News on KAPA
Kairos Pharma Transcript: AGM 2026

Jun 29, 2026, 12:00 PM EDT - 5 days ago

Kairos Pharma Transcript: AGM 2026


Kairos Pharma Proxy statement: Proxy filing

May 26, 2026, 8:00 AM EDT - 5 weeks ago

Kairos Pharma Proxy statement: Proxy filing


Kairos Pharma Proxy statement: Proxy filing

May 22, 2026, 8:00 AM EDT - 6 weeks ago

Kairos Pharma Proxy statement: Proxy filing


Kairos Pharma Slides: Investor presentation

May 15, 2026, 7:00 AM EDT - 7 weeks ago

Kairos Pharma Slides: Investor presentation


Kairos Pharma Quarterly report: Q1 2026

May 13, 2026, 7:00 AM EDT - 7 weeks ago

Kairos Pharma Quarterly report: Q1 2026


Kairos Pharma, Ltd. to Present at the LD Micro Invitational XVI

May 13, 2026, 5:30 AM EDT - 7 weeks ago

Kairos Pharma, Ltd. to Present at the LD Micro Invitational XVI


Kairos Pharma Proxy statement: Proxy filing

May 11, 2026, 8:00 AM EDT - 7 weeks ago

Kairos Pharma Proxy statement: Proxy filing


Kairos Pharma Annual report: Q4 2025

Mar 31, 2026, 7:00 AM EDT - 3 months ago

Kairos Pharma Annual report: Q4 2025


Kairos Pharma to acquire CL-273 from Celyn Therapeutics

2026-03-02T11:53:03.000Z - 4 months ago

Kairos Pharma to acquire CL-273 from Celyn Therapeutics


Kairos Pharma Registration statement: Registration Filing

Jan 13, 2026, 7:00 AM EST - 6 months ago

Kairos Pharma Registration statement: Registration Filing


Kairos Pharma files $75M mixed securities shelf

2026-01-13T11:05:46.000Z - 6 months ago

Kairos Pharma files $75M mixed securities shelf


Kairos Pharma Quarterly report: Q3 2025

Nov 14, 2025, 7:00 AM EST - 8 months ago

Kairos Pharma Quarterly report: Q3 2025


Kairos Pharma Provides Shareholder Update

Nov 4, 2025, 8:00 AM EST - 8 months ago

Kairos Pharma Provides Shareholder Update


Kairos Pharma Transcript: Study Update

Sep 18, 2025, 5:00 PM EDT - 10 months ago

Kairos Pharma Transcript: Study Update


Kairos Pharma Press release: Study Update

Sep 18, 2025, 5:00 PM EDT - 10 months ago

Kairos Pharma Press release: Study Update


Kairos Pharma announces interim efficacy analysis of ENV105

2025-09-18T12:16:01.000Z - 10 months ago

Kairos Pharma announces interim efficacy analysis of ENV105


Kairos Pharma Quarterly report: Q2 2025

Aug 12, 2025, 4:00 PM EDT - 11 months ago

Kairos Pharma Quarterly report: Q2 2025


Kairos Pharma management to meet with Maxim

2025-08-04T14:05:21.000Z - 11 months ago

Kairos Pharma management to meet with Maxim


Why Is Kairos Pharma Stock (KAPA) Up 170% Today?

2025-07-16T01:26:00.000Z - 1 year ago

Why Is Kairos Pharma Stock (KAPA) Up 170% Today?


Kairos Pharma Proxy statement: Proxy Filing

May 16, 2025, 8:00 AM EDT - 1 year ago

Kairos Pharma Proxy statement: Proxy Filing


Kairos Pharma, Ltd. Announces Participation in the D.

May 6, 2025, 8:00 AM EDT - 1 year ago

Kairos Pharma, Ltd. Announces Participation in the D.


Kairos Pharma Proxy statement: Proxy Filing

May 6, 2025, 8:00 AM EDT - 1 year ago

Kairos Pharma Proxy statement: Proxy Filing


Kairos Pharma Proxy statement: Proxy Filing

May 1, 2025, 8:00 AM EDT - 1 year ago

Kairos Pharma Proxy statement: Proxy Filing


Kairos Pharma Ltd. Provides Letter to Stockholders

Apr 24, 2025, 8:00 AM EDT - 1 year ago

Kairos Pharma Ltd. Provides Letter to Stockholders


Kairos Pharma Registration statement: Registration Filing

Apr 22, 2025, 8:00 AM EDT - 1 year ago

Kairos Pharma Registration statement: Registration Filing


Kairos Pharma Annual report: Q4 2024

Apr 14, 2025, 6:00 PM EDT - 1 year ago

Kairos Pharma Annual report: Q4 2024


Kairos Pharma initiated with a Buy at H.C. Wainwright

2025-04-03T10:16:23.000Z - 1 year ago

Kairos Pharma initiated with a Buy at H.C. Wainwright


Kairos Pharma completes safety lead-in of ENV105 trial

2025-03-31T11:11:12.000Z - 1 year ago

Kairos Pharma completes safety lead-in of ENV105 trial


Kairos Pharma initiated with a Buy at Maxim

2025-03-27T11:40:11.000Z - 1 year ago

Kairos Pharma initiated with a Buy at Maxim


Kairos Pharma announces new DoD funding for ENV205 research

2025-02-18T13:42:31.000Z - 1 year ago

Kairos Pharma announces new DoD funding for ENV205 research


Kairos Pharma Registration statement: Registration Filing

Jan 29, 2025, 7:00 AM EST - 1 year ago

Kairos Pharma Registration statement: Registration Filing


Kairos Pharma Provides Business Update and Outlook into 2025

Jan 21, 2025, 8:30 AM EST - 1 year ago

Kairos Pharma Provides Business Update and Outlook into 2025


IBN Initiates Coverage of Kairos Pharma Ltd.

Nov 26, 2024, 8:30 AM EST - 1 year ago

IBN Initiates Coverage of Kairos Pharma Ltd.


Kairos Pharma Quarterly report: Q3 2024

Nov 13, 2024, 6:00 PM EST - 1 year ago

Kairos Pharma Quarterly report: Q3 2024


Kairos Pharma Earnings release: Q3 2024

Nov 13, 2024, 6:00 PM EST - 1 year ago

Kairos Pharma Earnings release: Q3 2024


Kairos Pharma to Present at the LD Micro Main Event XVII

Oct 22, 2024, 9:00 AM EDT - 1 year ago

Kairos Pharma to Present at the LD Micro Main Event XVII


Kairos Pharma Closing of $6.2 Million Initial Public Offering

Sep 17, 2024, 4:29 PM EDT - 1 year ago

Kairos Pharma Closing of $6.2 Million Initial Public Offering


Kairos Pharma Prices $6.2 Million Initial Public Offering

Sep 16, 2024, 10:49 AM EDT - 1 year ago

Kairos Pharma Prices $6.2 Million Initial Public Offering


Kairos Pharma Registration statement: Registration Filing

Aug 16, 2024, 8:00 AM EDT - 2 years ago

Kairos Pharma Registration statement: Registration Filing


Kairos Pharma Registration statement: Registration Filing

Jun 4, 2024, 8:00 AM EDT - 2 years ago

Kairos Pharma Registration statement: Registration Filing


Kairos Pharma Registration statement: Registration Filing

May 24, 2024, 8:00 AM EDT - 2 years ago

Kairos Pharma Registration statement: Registration Filing


Kairos Pharma Registration statement: Registration Filing

May 20, 2024, 8:00 AM EDT - 2 years ago

Kairos Pharma Registration statement: Registration Filing


Kairos Pharma Registration statement: Registration Filing

May 13, 2024, 8:00 AM EDT - 2 years ago

Kairos Pharma Registration statement: Registration Filing


Kairos Pharma Registration statement: Registration Filing

May 1, 2024, 8:00 AM EDT - 2 years ago

Kairos Pharma Registration statement: Registration Filing


Kairos Pharma to sell 1.55 million shares in IPO at $4 each

Feb 14, 2024, 6:16 PM EST - 2 years ago

Kairos Pharma to sell 1.55 million shares in IPO at $4 each


Oldshoe
Oldshoe Jul. 4 at 4:55 PM
$KAPA Bullish based on current stock price and current market opinion of KAPA (both low). NFA
0 · Reply
Oldshoe
Oldshoe Jul. 4 at 4:53 PM
$KAPA I estimate split by ~7/15, announcement two days prior. IB6 restrictions apply (expect IB6 restrictions continue to apply into Q4) - so price decline means it's to company's advantage to do any cash raise soon - but the compliance situation means it's unlikely pre-split. Inflow needed for cash raise, so catalyst needed. First catalyst (smaller one, there are potentially several) likely to occur as early as a few days after split, or later in Q3. Subsequent catalysts in Q3/Q4 - when everything is in place and company timing - company currently has over two quarters' cash on hand. Very much aware of January S-3 dollar amount - but their actual current ATM ability is only ~$2 million. Even that much could be absorbed by the market fairly easily during a high volume favorable catalyst situation (but would expect some moderation on ATM sells). Some variation of that scenario. Straight up opinion only, not financial advice, do your own due diligence before investing in a stock.
0 · Reply
Xtracked
Xtracked Jul. 3 at 3:35 PM
$KAPA MNTS got approved for NASA contract yesterday. Benzinga views NASA files. I expect a formal PR next week. ;) NFA
0 · Reply
Xtracked
Xtracked Jul. 3 at 3:31 PM
$KAPA I got out last week, already made $ w funds. This was the farthest I've gone w a carrot dangling in front on me. Never again. I'll be back as well to take advantage of this POS as much as possible.
0 · Reply
ezcheezie
ezcheezie Jul. 2 at 5:52 PM
$KAPA My positition is finally closed out. GLTA, I'll keep this on my watch list, but I'm not touching it until after the R/S.
0 · Reply
Xtracked
Xtracked Jul. 2 at 9:46 AM
0 · Reply
Xtracked
Xtracked Jul. 2 at 9:42 AM
$KAPA Whos buying this trash? They will end up diluting before they lie about any results . "Collaborations will continue thru 2027".. that'll be the PR they will present
0 · Reply
stockforce123
stockforce123 Jul. 1 at 8:42 PM
$KAPA “key collaborations with pharmaceutical companies that test the synergy of ENV-105 with oncology drugs for prostate cancer by end of Q2/beginning of Q3 2026”. JNJ
0 · Reply
stockforce123
stockforce123 Jul. 1 at 4:19 PM
$KAPA Jumped back in today with $10K. The CEO said collaboration with BP will be announced by early Q3. It could be JNJ.
0 · Reply
Oldshoe
Oldshoe Jul. 1 at 12:07 AM
$KAPA Outcome of vote removes some uncertainty. Delisting risk effectively removed since they can r/s. Company has adequate mkt cap.
0 · Reply
Xtracked
Xtracked Jun. 30 at 10:08 PM
$KAPA Vote was a joke. I'm guessing 1:20 on the split. PLUS!!! Now they can dilute, and give themselves pay increases AND continue to dilute on a regular basis in the future!!! Isn't that fkn awesome! TOTAL POS YU SHOULD BE INVESTIGATED. So many better investments out there... truly
0 · Reply
Oldshoe
Oldshoe Jun. 30 at 9:47 PM
$KAPA Voting results. https://www.sec.gov/ix?doc=/Archives/edgar/data/0001962011/000149315226031328/form8-k.htm
0 · Reply
Oldshoe
Oldshoe Jun. 30 at 6:10 PM
$KAPA Would be surprised to see it today. But to me a close above 0.41 would be a bullish indicator. There are Q3 catalysts expected, not necessarily expecting much further decline before they occur.
1 · Reply
ezcheezie
ezcheezie Jun. 29 at 3:51 PM
$KAPA Lets see what other false promises they'll feed us today.
0 · Reply
dvir1805
dvir1805 Jun. 29 at 1:40 PM
$KAPA pice of shit
0 · Reply
Xtracked
Xtracked Jun. 29 at 2:55 AM
$KAPA Garbage
0 · Reply
Oldshoe
Oldshoe Jun. 27 at 1:05 AM
$KAPA This should be the link to the shareholder meeting on Monday. www.virtualshareholdermeeting.com/KAPA2026
2 · Reply
Xtracked
Xtracked Jun. 26 at 3:08 PM
$KAPA Vote is definitely passing. They will bleed next week. 10 days more to make split effective...more blood. They have completely fkd retail investors... dangling a carrot in front for months. I suggest contacting Rosenberg. Classic corrupt behavior
0 · Reply
Haza4462
Haza4462 Jun. 26 at 11:53 AM
$KAPA Tell us what's next
0 · Reply
Oldshoe
Oldshoe Jun. 26 at 11:53 AM
$KAPA $KAPA Prior to 3:50 pm yesterday it appeared to me the stock has not recently been shorted much. Large drop at that time coincided with large decrease of shortable share availability, driving price below previous ATL (0.40). Further reduction in shortable share availability this morning. Likely to see further short term downside volatility leading into 6/29 meeting. The meeting itself should be a driver up/down on stock price. To me a reclaim of 0.41 should be short term bullish, that was approximately where yesterday's large drop originated. Only my speculation, not financial advice.
1 · Reply
uptrend2025
uptrend2025 Jun. 24 at 11:24 AM
$KAPA 👀
0 · Reply
Tracey11
Tracey11 Jun. 23 at 4:33 PM
$KAPA On Watch
0 · Reply